Human Placental Lactogen: Physiology and What Research Reports

What Human Placental Lactogen Is

Human placental lactogen (hPL), also written as human chorionic somatomammotropin (hCS), is a single-chain peptide hormone of pregnancy. It is encoded within the growth hormone gene cluster and is a close structural relative of human growth hormone and prolactin, which is why the same hormone family names recur throughout the literature on it. In pregnancy it becomes one of the most abundantly secreted placental products, and it is measured in maternal serum rather than in fetal blood, because the great majority of what the placenta makes is released toward the mother.

Because hPL sits in the growth hormone/prolactin family, structural biologists have studied how it engages receptor surfaces. A 2006 structural study reported a crystal structure of human placental lactogen and analysed the binding energetics of its site 1 receptor-binding surface (PMID 16546209). That kind of work explains why a hormone so similar in sequence to growth hormone behaves differently at receptors, and it is the reason hPL is often discussed alongside somatotropin-family peptides rather than on its own.

Where It Is Produced and How It Reaches Maternal Blood

hPL is synthesised by the syncytiotrophoblast, the multinucleated outer cell layer of placental villi that faces maternal blood in the intervillous space. Research on placental transfer mechanisms has described syncytiotrophoblast-derived vesicles within the placental intervillous space, a route by which placental contents reach the maternal circulation (PMID 16813758). Because production is tied to functioning trophoblast tissue, investigators have repeatedly asked whether circulating hPL tracks placental mass and placental health.

Transcriptional control has also been mapped. An earlier molecular study reported that the transcription factor activator protein-2 regulated human placental lactogen gene expression (PMID 10715552). Findings like that help explain why hPL output rises as trophoblast differentiates rather than appearing at a constant level throughout gestation.

What the Hormone Does in the Body

Textbook physiology places hPL among the hormones involved in maternal metabolic adaptation and in preparing mammary tissue, and laboratory studies have examined both themes directly. A 2023 tissue study examined the pattern of human placental lactogen expression across normal, lactational and malignant mammary epithelium and reported that expression differed across those tissue states (PMID 36945262). That work is descriptive immunohistochemistry, not a treatment study, but it shows why the "lactogen" half of the name persists.

Immune cells have also been studied in culture. An in vitro study examined the effects of human placental lactogen on the expression of CD163 and CD14 on human monocytes and reported that the hormone altered expression of these monocyte surface markers (PMID 11985517). Researchers use experiments of that kind to ask whether placental hormones contribute to the shift in maternal immune phenotype seen in pregnancy.

How hPL Is Measured and Studied

In practice, hPL is nearly always an analyte: it is measured in maternal serum by immunoassay and interpreted against gestational age. Investigators have then tested whether those values carry information beyond routine markers.

These are association studies in defined populations, and none of them established hPL as a stand-alone diagnostic test. They do explain why a reader encountering "placental lactogen" on a research protocol or a laboratory panel is usually looking at a marker of placental function.

hPL and Maternal Mood Research

A distinct strand of literature has asked whether placental hormone levels relate to maternal psychological measures. A 2024 study tracked human placental lactogen and oxytocin across pregnancy and reported individual hormone patterns together with associations with maternal-fetal attachment, anxiety and depression (PMID 38723407). A 2020 study reported that low serum placental lactogen at term was associated with postnatal symptoms of depression and anxiety in women delivering female infants (PMID 32247203). Related placental-biology work reported that maternal prenatal depression was associated with decreased placental expression of the imprinted gene PEG3 (PMID 27523184). These are observational findings about correlation, and the authors of such work generally describe mechanisms as unresolved.

Why the Term Matters to Peptide Readers

hPL turns up in peptide reading for three reasons. First, it is an endogenous peptide hormone in the same family as growth hormone and prolactin, so comparative structural work on it appears in the somatotropin literature (PMID 16546209). Second, it is a standard placental-function analyte, so it appears as an outcome measure in pregnancy studies (PMID 38243348). Third, it is sometimes confused with unrelated pregnancy peptides such as hCG, which is a different hormone with a different structure and different assays.

What the Cited Literature Did Not Cover

• None of the studies cited on this page administered human placental lactogen to human participants, so no dose, schedule or route is described here.
• The cell-culture work examined monocyte marker expression in vitro rather than clinical outcomes (PMID 11985517).
• Screening and marker studies reported associations within their own cohorts (PMID 31391722).

Adverse Events and Safety Signals: What Studies Report

The verified literature summarised here consists of structural, molecular, tissue-expression and observational human studies, not administration trials, so it contains no adverse-event profile for hPL given as a compound. What it does contain are signals attached to naturally occurring levels: researchers reported that low serum placental lactogen at term was associated with postnatal depression and anxiety symptoms in one cohort subgroup (PMID 32247203), and a separate study reported altered serum hPL in ultrasound-evaluated pregnancy-induced hypertension (PMID 38243348). Deviations in hPL in the aneuploidy-screening literature were reported as marker differences rather than as harms caused by the hormone (PMID 17154235). This page is for educational purposes only and is not medical advice; consult a licensed physician about pregnancy, hormone testing or laboratory results.

Reading the Evidence Carefully

Most hPL research is cross-sectional or cohort-based, sample sizes vary, and immunoassay platforms differ between laboratories, which limits direct comparison of absolute concentrations between papers. Gestational age dominates hPL values, so any reported difference is only interpretable against a matched reference. Mechanistic claims drawn from cultured cells or from tissue staining have not been shown to translate into clinical effects in the cited work. Taken together, the literature describes hPL as an abundant, structurally characterised placental peptide whose measured level carries information about placental function, and as a hormone whose broader physiological roles are still being mapped.

References

• Crystal structure and site 1 binding energetics of human placental lactogen (Journal of Molecular Biology, 2006)
• Activator protein-2 regulates human placental lactogen gene expression (Molecular and Cellular Endocrinology, 2000)
• Syncytiotrophoblastic vesicles in placental intervillous space (American Journal of Obstetrics and Gynecology, 2006)
• The Pattern of Expression of Human Placental Lactogen Across Normal, Lactational, and Malignant Mammary Epithelium (Cureus, 2023)
• Effects of human placental lactogen on the expression of CD163 and CD14 on human monocytes in culture (Clinical and Experimental Immunology, 2002)
• Role of Maternal Serum Human Placental Lactogen in First Trimester Screening (Indian Journal of Clinical Biochemistry, 2019)
• Human placental lactogen is a first-trimester maternal serum marker of Down syndrome (Prenatal Diagnosis, 2007)
• Serum Human Placental Lactogen Assays in Ultrasound Evaluated Pregnancy-Induced Hypertension: A Marker of Placental Function in Pregnancy (Nigerian Journal of Physiological Sciences, 2023)
• Elevated Maternal Folate Status and Changes in Maternal Prolactin, Placental Lactogen and Placental Growth Hormone Following Folic Acid Food Fortification (Nutrients, 2023)
• Human placental lactogen (human chorionic somatomammotropin) and oxytocin during pregnancy: Individual patterns and associations with maternal-fetal attachment, anxiety, and depression (Hormones and Behavior, 2024)
• Low serum placental lactogen at term is associated with postnatal symptoms of depression and anxiety in women delivering female infants (Psychoneuroendocrinology, 2020)
• Maternal prenatal depression is associated with decreased placental expression of the imprinted gene PEG3 (Psychological Medicine, 2016)